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Objective: To evaluate adherence to antihypertensive therapy (AHT) and the association 
between adherence to AHT, all-cause mortality, and cardiovascular (CV) morbidity in a large 
cohort of patients newly treated with antihypertensives in a clinical practice setting.
Methods: An administrative database kept by the Local Health Unit of Florence (Italy) listing 
patient baseline characteristics, drug prescription, and hospital admission information was 
used to perform a population-based retrospective study including patients newly treated with 
antihypertensives, $18 years of age, with a first prescription between January 1, 2004 and 
December 31, 2006. Patients using antihypertensives for secondary prevention of CV disease, 
occasional spot users, and patients with early CV events, were excluded from the study cohort. 
Adherence to AHT was calculated and classified as poor, moderate, good, and excellent. A Cox 
regression model was conducted to determine the association among adherence to AHT and 
risk of all-cause mortality, stroke, or acute myocardial infarction.
Results: A total of 31,306 patients, 15,031 men (48.0%), and 16,275 women (52.0%), with 
a mean age of 60.2 ± 14.5 years was included in the study. Adherence to AHT was poor in 
8038 patients (25.7% of included patients), moderate in 4640 (14.8%), good in 5651 (18.1%), 
and excellent in 12,977 (41.5%). Compared with patients with poor adherence (hazard ratio 
[HR] = 1), the risk of all-cause death, stroke, or acute myocardial infarction was significantly 
lower in patients with good (HR = 0.69, P , 0.001) and excellent adherence (HR = 0.53, 
P , 0.001).
Conclusions: These findings indicate that suboptimal adherence to AHT occurs in a substantial 
proportion of patients and is associated with poor health outcomes already in primary prevention 
of CV diseases. For health authorities, this preliminary evidence underlines the need for 
monitoring and improving medication adherence in clinical practice.
Keywords: antihypertensive drug therapy, adherence, all-cause mortality, stroke, acute 
myocardial infarction
Introduction
Clinical trials have shown that continuous treatment with antihypertensive drug therapy 
(AHT) significantly lowers blood pressure in a very high proportion of patients, thus 
significantly decreasing both cardiovascular (CV) morbidity and mortality1–4 and, 
ultimately, overall costs associated with high blood pressure.5–7
However, in clinical practice, adherence (whether a patient takes medications as 
prescribed) and persistence (whether a patient remains on therapy as long as needed) 
to AHT are suboptimal,8–11 ranging from 30% to 70%, depending on measurement 
methods and definitions.12,13 Poor adherence to AHT causes suboptimal blood pressure 
control and, ultimately, preventable CV morbidity, hospitalizations, mortality, and ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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health care expenditure,10,14–16 all consequences that have 
been documented, but still remain overlooked.
The objective of this study was to evaluate adherence to 
AHT and the association between adherence to AHT, all-cause 
mortality, and hospitalizations for stroke and acute myocardial 
infarction (AMI) in a large cohort of patients newly treated 
with antihypertensives in a clinical practice setting.
Patients and methods
Data source
The study was based on administrative databases maintained 
by the Local Health Unit (LHU) of Florence, Italy, with a 
population of approximately 800,000 inhabitants. The LHU 
Ethics Committee approved the study. In the Medications 
Prescription Database, the LHU routinely measures the 
volume of expenditure generated by the dispensing of drugs 
to the enrollees. The data available in each prescription claim 
include the patient’s national health number, the prescribing 
physician’s number, the ATC (anatomical-therapeutic-
  chemical) code of the drug delivered, the number of packs, the 
number of units per pack, the dosages, the unit cost per pack, 
and the prescription date. Using the numeric code released to 
each citizen by the LHU as a unique identifier, this database was 
linked with the Beneficiaries’ Database, listing some patients’ 
demographic characteristics such date of birth, sex, place of 
residence, physician licence number, and registration and end of 
registration date, and the Hospital Discharge Database, which 
includes all hospitalization data with the discharge diagnosis 
codes classified according to the International Classification of 
Diseases, Ninth Revision (ICD 9), and the Mortality Database, 
where death data are recorded. It was not possible to retrieve 
the cause of death from death certificates. Universal health-care 
coverage in Italy allows completeness and comprehensiveness 
of the information contained in these databases, which have 
been used in previous epidemiological studies.17 The Italian 
Ministry of Health reported that Tuscany archives are 100% 
complete and 95% accurate.18
In order to guarantee patient privacy, each subject was 
assigned an anonymous univocal alphanumeric code.
Cohort definition
This was a retrospective cohort study, which included only 
new AHT users, $18 years of age, with a complete his-
tory of prescriptions and clinical outcome data over the 
study period. Subjects were enrolled if they had at least 1 
prescription of AHT (diuretics [ATC code C03], excluding 
loop diuretics [ATC code C03C] which are mainly used for 
heart failure, β-blockers [ATC code C07], calcium-channel 
blockers [ATC code C08], angiotensin-converting enzyme 
  inhibitors [ATC code C09A/B], angiotensin-receptor blockers 
[ATC code C09C/D], or other AHT drugs [ATC code C02]) 
dispensed between January 1, 2004 and December 31, 2006 
(enrolment period). The date of the first AHT claim was 
defined as the enrolment date. Subjects were defined new 
users if they had not been prescribed any AHT between 
January 1, 2002 and the enrolment date.
In order to prevent inclusion of subjects prescribed with 
any of the index drugs for indications other than hypertension, 
we excluded subjects who had been diagnosed with heart 
failure (ICD9 code 428.x), ischemic heart disease (ICD9 
code 410 through 414.x), cerebrovascular disorders (ICD9 
code 430 through 438.x), or other CV diseases (ICD9 code 
390 through 400.x, 406 through 459 excluding the afore-
mentioned diagnosis codes) before the enrolment date and 
those prescribed with nitrates in the year before the enrolment 
date.19 Furthermore, we also excluded records of subjects 
who died, moved to other LHU or were hospitalized with 
a diagnosis of stroke or AMI in the 6 months after the 
enrolment date, in order to ensure a minimum time interval 
for adherence assessment: in fact, the use of short-term time 
intervals to assess adherence has been shown not to reflect 
accurately long-term behaviors.20,21
Adherence to AHT
Adherence to AHT was estimated as the percentage of days 
a subject had tablets available (proportion of days covered, 
PDC), from the first delivery of AHT until either death, moving 
to another LHU, hospitalization for AMI or stroke, or July 1, 
2007, whichever occurred earlier. The interval was separated 
into treatment episodes of continuous AHT use based on the 
method of Catalan and LeLorier.22 A treatment episode was 
measured as the time-span between the starting date of the first 
AHT dispensing until the last day of the final AHT supply. The 
latter date included allowance for a possible gap after the final 
dispensing within the specific episode. Prescriptions filled near 
the end of the interval contributed days till that date.
Prescriptions containing more than 1 drug contributed 
a) the sum of the days’ supply of all drugs, in case of drugs 
from the same AHT drug class, because a possible stockpil-
ing of medication was considered; b) the lower days’ supply 
drug value, in case of drugs from different AHT drug classes, 
identifying them as a combined therapy.
The PDC corresponded to the total of number of days’ 
supply of medication dispensed within each episode, ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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divided by the total length of the interval and multiplied 
by 100. Subjects were grouped into 4 adherence categories 
as follows: poor (PDC # 40%), moderate (PDC 41% to 
60%), good (PDC 61% to 80%), and excellent adherence 
(PDC . 80%). When PDC was #20%, indication for AHT 
treatment was considered uncertain or questionable and, there-
fore, the corresponding subjects were excluded,23 of whom 
77.2% received only 1 and 14.6% only 2 prescriptions.
Outcomes
Study outcomes were all-cause mortality and the first hos-
pitalization for fatal or nonfatal CV events, represented by 
a principal discharge diagnosis of AMI (ICD 9 code 410.x) 
or stroke (ICD 9 codes 430 through 438.x). Patients were 
followed-up from the date of enrolment until study closure 
(December 31, 2007) or the date of cancellation from 
the enrollees’ list in the LHU of Florence. Median follow-up 
duration was 1.9 years, with a maximum of 3.5 (first 6 months 
after the enrolment date excluded).
Statistical analysis
Data were summarized as mean ± standard deviation (SD) 
for continuous variable and as numbers (percentages) of 
subjects for categorical variables. Pearson’s chi-square and 
one-way ANOVA tests were used to evaluate differences in 
baseline characteristics across adherence levels.
Bivariate and multivariable Cox proportional hazard 
regression models (Table 2, Models 1 and 2, respectively) 
were used to estimate hazard ratios (HR) and 95% confidence 
intervals (CI) of death and CV events, as combined and 
separate outcomes, as a function of adherence categories. 
To adjust for potential confounders, in the multivariable 
model we included age, gender, and presence of specific 
treatments in the year prior to the enrolment date, taken as 
proxies for the diagnoses of diabetes mellitus (hypoglycemic 
agents, ATC code A10), dyslipidemia (hypolipidemic 
agents, ATC code C10), heart disease (cardiac therapy, ATC 
code C01, excluding nitrates, ATC code C01DA), and 
  atherosclerotic disease (platelet aggregation inhibitors, ATC 
cod B01AC). Visual inspection of the survival curves 
confirmed that the assumption of proportional hazards was 
not violated.
Sensitivity analyses were used to assess the robustness 
of our analysis in the presence of potential biases.
Two-tailed P-values , 0.05 were considered statistically 
significant. All analyses were conducted using SPSS for 
Windows, version 15.0.
Results
Out of an initial selection of 63,027 records of a new 
prescription for AHT agents, 31,721 (50.3%) were excluded 
because of hospitalization for CV disease prior to enrolment 
(2,896, 4.6%), use of nitrates in the previous year (539, 
0.9%), cancellation from the LHU list or occurrence of a 
study outcome in the 6 months after enrolment (1269, 2.0%), 
or PDC # 20% (27,017, 42.8%). Thus, 31,306 patients 
(15,031 men, 48.0%) were included, whose mean age was 
60.2 ± 14.5 years (range 18 to 101 years). Use of hypoglycemic 
agents, lipid-modifying agents, cardiac therapy, and platelet 
aggregation inhibitors is shown in Table 1.
Adherence to AHT
Adherence to AHT was poor in 8038 patients subjects 
(25.7%), moderate in 4640 (14.8%), good in 5651 (18.1%), 
and excellent in 12,977 (41.5%) (Table 1). Poorly adherent 
patients were younger, predominantly women, and with 
lower prevalence of associated hypoglycemic, lipid-lowering, 
and platelet aggregation inhibitor agents (Table 1), whereas 
use of cardiac therapy was limited, uncommon, and unrelated 
to adherence level.
Table 1 Characteristics of subjects newly treated with antihypertensive medications, by level of adherence to treatment
Adherencea Total
Poor Moderate Good Excellent P value
Subjects, n (%) 8038 (25.7) 4640 (14.8) 5651 (18.1) 12977 (41.5) 31306 (100.0)
Age, mean (SD), years 57.3 (17.3) 60.3 (15.2) 61.6 (13.5) 61.4 (12.5) ,0.001 60.2 (14.5)
Male (%) 43.6 43.9 45.0 53.5 ,0.001 48.0
Associated drug therapyb
  Hypoglycemic agents (%) 4.4 5.2 5.6 7.0 ,0.001 5.8
  Lipid lowering agents (%) 4.3 4.6 4.9 5.3 0.007 4.9
  Cardiac therapy (%) 1.3 1.7 1.3 1.6 0.190 1.5
  Platelet aggregation inhibitors (%) 5.8 6.1 7.2 7.1 ,0.001 6.6
Notes: aDefined on the basis of the proportion of days covered (PDC): poor, PDC # 40%; moderate, PDC 41% to 60%; good, PDC 61% to 80%; excellent, PDC . 80%. 
bOne year before the enrolment date.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Health outcomes
Out of 31,306 patients, a total of 1263 (4.0%) combined 
endpoints was seen in the follow-up, including 768 deaths, 
370 strokes, and 191 AMI. Incidence of the combined endpoint 
decreased significantly with increasing adherence, being 
29.5, 24.8, 19.6, and 16.1 per 1000 person-years in patients 
whose adherence was poor, moderate, good, and excellent, 
respectively. The corresponding bivariate HRs are shown in 
Table 2, Model 1. This association remained unaffected when 
adjusting for covariates in multivariable Model 2, Table 2 and 
Figure 1: the risk of the combined endpoint increased stepwise 
with decreasing adherence as well as with advancing age, 
was greater in males and in users of hypoglycemic agents or 
platelet aggregation inhibitors or cardiac therapy, and lower in 
the presence of treatment with lipid-lowering agents.
The results obtained for the individual endpoints in 
separate analyses were similar for the outcome of all-cause 
mortality, as shown by P for trend values (Table 3 and 
Figure 2). The analyses for the outcomes of stroke and AMI 
showed no statistically significant differences between 
individual levels of adherence and the study outcome 
(Table 3 and Figures 3 and 4).
Sensitivity analysis
To examine the robustness of our results, we did several 
additional analyses.
First, to ensure that our method did not introduce a 
survival bias, we re-estimated the association between 
adherence-study outcomes among subjects surviving and 
free of AMI or stroke for at least 3 months and 1 year after 
the enrolment date.
Second, the primary categorization of adherence based 
on PDC level: poor (PDC # 40%), moderate (PDC, 41% to 
60%), good (PDC, 61% to 80%), excellent (PDC . 80%) was 
Table 2 Adherence to antihypertensive medications and risk of the combined outcome of all-cause death, stroke, or acute myocardial 
infarction, estimated by Cox proportional hazards models
Model 1 Model 2
HR (95% CI) P value HR (95% CI) P value
Adherencea ,0.001a ,0.001b
Poor 1.00 1.00
Moderate 0.94 (0.80–1.11) 0.464 0.87 (0.74–1.03) 0.104
Good 0.77 (0.65–0.90) 0.001 0.69 (0.58–0.81) ,0.001
Excellent 0.61 (0.53–0.70) ,0.001 0.53 (0.46–0.61) ,0.001
Age, years
,45 – – 1.00
45–65 – – 2.67 (1.84–3.88) ,0.001
.65 – – 10.48 (7.31–15.03) ,0.001
Gender 
Male – – 1.00
Female – – 0.62 (0.55–0.69) ,0.001
Associated drug therapyc,d
Hypoglycemic agents – – 1.67 (1.41–1.99) ,0.001
Lipid-lowering agents – – 0.70 (0.54–0.91) 0.006
Cardiac therapy – – 1.69 (1.29–2.23) ,0.001
Platelet aggregation inhibitors – – 1.66 (1.42–1.93) ,0.001
Notes: Bivariate and multivariable risks are shown in Models 1 and 2, respectively; a total of 1263 events in 31,306 subjects was considered in the models; adefined as in 
Table I; bfor trend; cabsence of medication as reference; done year before the enrolment date.
Abbreviations: CI, confidence interval; HR, hazard ratio.
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Figure  1  Combined  endpoint  of  all-cause  death,  stroke,  or  acute  myocardial 
infarction  (AMI)  curves  in  31,340  subjects  newly  treated  with  antihypertensive 
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arbitrary. However, we examined the effect of medication 
adherence on outcomes using different definitions of 
PDC cutoffs: quartiles, #25%, 26% to 50%, 51% to 
75%, .75%.
Third, as previous studies described the relationship 
between CV disease severity factors, level of adherence 
to AHTs and, consequently, the development of adverse 
outcome events,19,23,24 to minimize the bias, the adherence-
study outcomes association was also evaluated across 
different risk subgroups: older patients (.65 years), patients 
with at least 1 medication evaluated in the year before the 
enrolment date.
The results of these additional analyses were consistent 
with our primary findings. Data are shown in Tables 4 and 5.
Discussion
Despite the considerable magnitude and the remarkable 
consequences of suboptimal adherence to AHT shown in 
randomized controlled trials as well as in observational 
studies,1–3 in clinical practice, evidence of the association 
between adherence to AHT, all-cause mortality, and CV 
morbidity is still limited. Existing publications focus on 
newly diagnosed hypertensive patients, diabetics, and patients 
with previous CV events – that is, mostly on secondary 
prevention. Studied outcomes include CV hospitalizations 
(mainly in primary prevention studies19,23,24), and all-cause 
hospitalizations or all-cause mortality (mainly in secondary 
prevention studies20,25–27). The present study analyzed all-
cause mortality, and the first occurrence of stroke and AMI 
among hypertensive patients newly treated with AHT, in 
primary prevention.
The risk of all-cause mortality, stroke, and AMI decreased 
progressively as adherence to AHT increased. Compared 
with poor adherence, the risk of experiencing a major health 
outcome decreased stepwise from good (31% lower risk) to 
excellent (47% lower risk) (Table 2). The risk gradient did 
not attain statistical significance in subjects with moderate 
  adherence, thus possibly suggesting some treatment 
effectiveness threshold. This is an original finding of the 
present study, due to the large number of records available, 
Table 3 Adherence to antihypertensive medications and risk of all-cause death, stroke, and acute myocardial infarction, estimated in 
separate multivariable Cox proportional hazards models
All-cause death Stroke Acute myocardial infarction
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Adherencea ,0.001b 0.381b 0.877b
Poor 1.00 1.00 1.00
Moderate 0.81 (0.66–0.99) 0.038 0.96 (0.69–1.33) 0.799 1.14 (0.71–1.83) 0.592
Good 0.59 (0.48–0.72) ,0.001 0.81 (0.59–1.11) 0.197 0.98 (0.62–1.55) 0.939
Excellent 0.37 (0.31–0.45) ,0.001 0.82 (0.63–1.07) 0.138 0.96 (0.65–1.40) 0.825
Notes: Totals of 768 deaths in 30,668 subjects and 370 strokes and 191 acute myocardial infarctions in 31,340 subjects were considered in the models; HRs with 95% CIs 
adjusted for age, gender, and use of hypoglycemic agents, lipid-lowering agents, cardiac therapy, and platelet aggregation inhibitors before the enrolment date; adefined as in 
Table I; bfor trend.
Abbreviations: CI, confidence interval; HR, hazard ratio.
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Figure 2 Incidence of all-cause mortality among new antihypertensive therapy users.
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which enabled the definition of 4 levels of adherence, whereas 
most of the previous studies referred to just 2 levels of 
adherence.19,23 As this is an observational study, the allocation 
of patients into different adherence groups was not random-
ized and it might have produced study groups not similar 
in their baseline CV risk profile. So this bias might have 
altered the observed reduction of the occurrence of events 
associated with increased adherence. However, the results 
obtained after controlling for baseline differences in the 
regression model and stratifyng the patient population into 
different risk subgroups in the sensitivity analisys confirmed 
the robustness of our findings.
In separate analyses of the individual endpoints, the 
risk associated with poor adherence was significant for all-
cause mortality and directionally similar for both stroke 
and AMI, though with lower, nonsignificant gradients. 
Thus, the present study shows that adherence to AHT is 
associated with a substantial reduction in mortality risk 
also in primary prevention, whereas previous findings were 
restricted to secondary prevention.20,25,26 In the analysis of 
the occurrence of each single health outcome, the reduction 
in the risk of stroke and AMI was lower than that reported 
by Breekveldt-Postma et al.19 However, in our study, the 
duration of the follow-up was much shorter (median of 
1.9 years in our study versus up to a maximum of 10 years) 
and the observed number of strokes (370 versus 1293) and 
AMI (191 versus 826) was lower. Another study, recently 
published by Mazzaglia et al, reported greater risk reduction 
with increasing adherence. Compared with the present study, 
the endpoint of the study by Mazzaglia et al was a combi-
nation of a wider range of CV events, not only stroke and 
AMI, and the follow-up available was longer and extended 
up to 4.6 years.24 Previous studies with almost the same 
follow-up duration (2.4 years) as ours reported higher risk 
reduction only in highest-risk patients (eg, patients with a 
previous episode of AMI20). Nevertheless, the favorable 
trend in reducing CV events is more evident for nonfatal 
stroke than nonfatal AMI, thus confirming that for cause-
specific events AHT is associated with a major reduction in 
the risk of fatal or nonfatal stroke, but coronary events are 
reduced as well, though to a lesser degree.6
Limitations
Several potential limitations of this study should be 
considered.
First, there was a lack of clinical data. The present study 
was conducted by cross-linking Medications Prescriptions 
Database with Health-assisted Subjects’ Database, Hospital 
Discharge Database, and Mortality Database. These ad hoc 
databases, comparable to the healthcare claim databases that 
have been utilized for years in United States and Canada for 
outcome research,28,29 were originally constructed to serve 
a billing role, the reimbursement for services provided. 
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Figure  4  Incidence  of  acute  myocardial  infarction  (AMI)  events  among  new 
antihypertensive therapy users.
Table 4 One-way sensitivity analysis for the risk of the combined outcome of all-cause death, stroke, or acute myocardial infarction
Adherencea
Moderate Good Excellent
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Absence of study outcomes for at least 3 months 0.94 (0.81–1.08) 0.374 0.70 (0.60–0.81) ,0.001 0.55 (0.50–0.64) ,0.001
Absence of study outcomes for at least 1 year 0.87 (0.71–1.07) 0.196 0.72 (0.59–0.88) 0.001 0.56 (0.47–0.67) ,0.001
Adherence categories: quartilesb 0.88 (0.72–1.07) 0.152 0.73 (0.64–0.83) ,0.001 0.51 (0.43–0.59) ,0.001
Adherence categories: #25, 26–50, 51–75, .75%c 0.83 (0.68–1.01) 0.058 0.72 (0.59–0.88) 0.002 0.50 (0.40–0.59) ,0.001
Age . 65 0.85 (0.71–1.03) 0.100 0.67 (0.55–0.79) ,0.001 0.52 (0.44–0.61) ,0.001
At least 1 comorbidity 0.96 (0.84–1.13) 0.417 0.70 (0.55–1.02) 0.059 0.54 (0.49–0.70) 0.006
Notes: aCases of proportion of days covered (PDC) # 20% were excluded; bthe first quartile corresponds to the poor category of adherence, the second quartile to the 
moderate category, the third quartile to the good category, the fourth quartile to the excellent category; cPDC # 25% corresponds to the poor category, PDC 26% to 50% 
to moderate, PDC 51% to 75% to good, PDC .75% to excellent.
Abbreviations: CI, confidence interval; HR, hazard ratio.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Thus, information on clinical data was not available and, 
as a consequence, the adjustment for blood pressure levels 
was not permitted.
However, the confounding effect of baseline blood pres-
sure on the association between adherence to AHT agents 
and CV events is probably limited, as suggested by a recent 
study in a general practice population, where baseline systolic 
and diastolic blood pressure values were comparable between 
low-, intermediate-, and high-adherence patients.24 Moreover, 
a recent meta-analysis of 147 trials30 showed a benefit in 
lowering blood pressure by antihypertensive drugs whatever 
the patients’ blood pressure was, thus avoiding the need to 
measure blood pressure routinely.
Second, a formal diagnosis of arterial hypertension was 
not available. In the present study, indeed, the diagnosis was 
surrogated by prescription of AHT, thus leaving room for 
potential misclassification, as only some of the subjects treated 
with AHT drugs may have been truly hypertensive. However, 
the exclusion of subjects with only 1 or 2 prescriptions and 
of those with previous hospitalizations or therapies for CV 
diseases should have minimized this misclassification.
Third, the measurement of drug use was based on dis-
pensed medications and actual drug-taking behaviors remain 
unknown. Empirical evidence suggests, however, a strong cor-
relation between pharmacy claims and drug exposure.31,32
Fourth, information bias may also have been possible. 
As hospital discharge information was obtained from the 
Florence Hospital Discharge Database, we could not track 
hospitalizations collected in other Italian LHUs’ databases.
Finally, the data source utilized did not allow for lifestyle 
adjustments, such as physical activity, smoking, and other 
determinants of CV morbidity and mortality. The potential 
confounding effect of these variables on the association 
between adherence and CV events should be analyzed in 
future studies.
Conclusions
The findings from the present study indicate that suboptimal 
adherence to AHT is associated with an avoidable number 
of all-cause deaths and hospitalizations for CV disease in 
primary prevention. In a public health perspective, this 
evidence underlines the need for monitoring and improving 
medications adherence in clinical practice. Studies based on 
administrative databases, like the present one, offer several 
advantages, including a prompt, easily updated, and repre-
sentative picture of the monitored cohorts for a prolonged 
duration of observation, with highly generalizable results.
Consequences of poor adherence with AHT extend beyond 
health prevention and involve costs for CV prevention and 
economic sustainability of national health services. Although 
the therapeutic benefits of AHT are well understood, the 
potential economic advantages are often overlooked in the 
public debate, which is dominated by concerns about escalat-
ing expenditure for prescription drugs. Increased drug utiliza-
tion can provide a net economic return when it is driven by 
improved adherence to guidelines-based therapy.16 Although 
drug costs are a relatively small percentage of total healthcare 
costs,33,34 they have high leverage – a small increase in drug 
costs (associated with improved adherence) can produce a 
much larger reduction in the general economic burden for 
health.
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Table 5 One-way sensitivity analysis for the risk of all-cause death
Adherencea
Moderate Good Excellent
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Absence of study outcomes for at least 3 months 0.86 (0.72–1.03) 0.095 0.60 (0.50–0.72) ,0.001 0.39 (0.35–0.48) ,0.001
Absence of study outcomes for at least 1 year 0.81 (0.63–1.04) 0.098 0.62 (0.48–0.79) ,0.001 0.39 (0.33–0.51) ,0.001
Adherence categories: quartilesb 0.79 (0.53–1.07) 0.103 0.61 (0.54–0.75) ,0.001 0.36 (0.30–0.42) ,0.001
Adherence categories: #25, 26–50, 51–-75, .75%c 0.84 (0.66–1.06) 0.140 0.60 (0.51–0.78) 0.001 0.35 (0.28–0.45) ,0.001
Age . 65 years 0.83 (0.64–1.07) 0.148 0.57 (0.41–0.73) ,0.001 0.36 (0.31–0.45) ,0.001
At least 1 comorbidity 0.75 (0.50–1.12) 0.162 0.59 (0.47–0.71) 0.001 0.40 (0.29–0.68) ,0.001
Notes: acases of proportion of days covered (PDC) #20% were excluded; bthe first quartile corresponds to the poor category of adherence, the second quartile to the 
moderate category, the third quartile to the good category, the fourth quartile to the excellent category; cPDC # 25% corresponds to the poor category, PDC 26% to 50% 
to moderate; PDC 51% to 75% to good, PDC . 75% to excellent.
Abbreviations: CI, confidence interval; HR, hazard ratio.ClinicoEconomics and Outcomes Research
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